https://www.selleckchem.com/pr....oducts/tiragolumab-a
5 vs. 50.0 years, 0.001; 41.7% vs. 6.1%, = 0.010; and 33.3% vs. 2.5%, = 0.003, respectively). ATDs were challenged in 14 cases. The ATD associated most often with SCAR cases was rifampin (81.8%), followed by isoniazid (66.7%), ethambutol (50.0%), pyrazinamide (33.3%). Six patients (42.9%) had hypersensitivity reactions to 2 or more drugs. DRESS was more common among the ATD-related SCAR cases. Although treatment with most ATDs carries the risk of SCAR development, the use of rifampin was most frequently involved in t
إعجاب
علق
شارك
